Stepping down deliberately, and how to do it without losing progress — what changed since
Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
I have deliberately not rounded that, because the rounding is where the argument starts.
Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.
I read post #64 twice before replying, because I had assumed the opposite.
Half steps are arithmetically simple and pharmacologically unstudied. They are not dangerous in any obvious way and they are also not what the evidence describes, and both halves of that should be said.
It is the sort of thing that seems obvious in retrospect and was not at the time.
Fine by me. I had wanted a stronger conclusion and there is not one available.
Building on post #84 rather than restating it.
Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.
That has held every time I have looked, which is not the same as always.
Confirming post #97 from a second method, which matters more than confirming it from a second person.
There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine".
I have separated what I observed from what I concluded, which does not always happen.
Read the full topic (100 posts)
This topic was referenced in
- Reaching a dose and staying there for a year: a longitudinal notePractice › Dosing & titration · 2 replies
- Follow-up: The lowest dose that does anything: is that a real question?Practice › Dosing & titration · 75 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: Holding a dose indefinitely: is there a documented downside?
The question in the title: Revisiting: Holding a dose indefinitely: is there a documented downside? I will give what I have already checked below so nobody repeats it. I have read the maintained page on this…
|
+26 | 30 | 4.5k | 18mo |
|
Reaching a dose and staying there for a year: a longitudinal note — does this still hold?
Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold? I have read the maintained page on this and I still have…
|
+35 | 39 | 547 | 11mo |
|
Follow-up: Where the four-week escalation interval comes from, and what it is not
Where the four-week escalation interval comes from, and what it is not Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about four-week escalation…
|
+131 | 147 | 47k | 18mo |
|
Micro-titration: a disputed topic, argued properly — one year on
Posting this under the heading it deserves: Micro-titration: a disputed topic, argued properly — one year on Everything below is what sits behind that. Reading back through what has been written here about…
|
+63 | 68 | 35k | 1d |
|
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept
Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept I have read the maintained page on this and I still have a gap, so I…
|
+7 | 11 | 26k | 9mo |
Related topics — sharing the tags tirzepatide, semaglutide, titration
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Putting the numbers in the first post, because a question about a…
|
2 | 63k | 5mo | |
|
Peak-to-trough ratio at steady state for a weekly agent — the long version
Peak-to-trough ratio at steady state for a weekly agent — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Peak-to-trough ratio,…
|
+57 | 61 | 708 | 1d |
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…
|
+150 | 163 | 22k | 11mo |
|
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…
|
+2 | 6 | 18k | 17mo |
|
Clearance pathways and what renal impairment changes
Clearance pathways and what renal impairment changes Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of clearance pathways is wrong? I…
|
+11 | 15 | 43k | 2mo |